Patent intelligence · US
US 2022380379
PHARMACEUTICAL COMPOUNDS
PHARMACEUTICAL COMPOUNDS
Patent details — US 2022380379
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 1, 2022
- Expiration
- Nov 26, 2042
- Applicant
- HEPTARES THERAPEUTICS LTD [GB]
- CPC classes
- A61K/3146, A61P 25/ 18 A I, A61P/2518, A61P/2528
Quick answer
US 2022380379 (PHARMACEUTICAL COMPOUNDS) is held by HEPTARES THERAPEUTICS LTD [GB]. Status: granted. Granted Dec 1, 2022. Expires Nov 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- HEPTARES THERAPEUTICS LTD [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/3146, A61P 25/ 18 A I, A61P/2518, A61P/2528, A61P/2900
More from HEPTARES THERAPEUTICS LTD [GB]
Related pharmaceutical patents in our USPTO index.
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted
Frequently asked questions
What is US patent 2022380379?
US 2022380379 (PHARMACEUTICAL COMPOUNDS) is held by HEPTARES THERAPEUTICS LTD [GB]. Status: granted. Granted Dec 1, 2022. Expires Nov 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2022380379?
HEPTARES THERAPEUTICS LTD [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2022380379 expire?
Our index shows an expiration date of Nov 26, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.